Light-Activated Microtransponders for Tagging Applications in Biomedical Laboratories (RFID Europe 2011)

Mr Wlodek Mandecki, President
PharmaSeq
United States
 
2011 9월27일.

Downloads

PharmaSeq presentation*
PharmaSeq audio*

If you already have access, please [Login]

Presentation Summary

  • Light-activated monolithic microtransponders ("p-Chips") have a niche in applications requiring small size/weight, stability to demanding operating conditions and low chip cost of the chip.
  • Recent progress and practical examples involving tagging of surgical tools in a healthcare setting and disposables used in diagnostic laboratory.
  • The identification of surgical tools is a demanding application because the RFID tag has to survive multiple rounds of sterilization as well as rough handing of the tools themselves.
  • Performance of the system has been demonstrated in a healthcare setting.

Speaker Biography (Wlodek Mandecki)

Dr. Wlodek Mandecki is President and Chief Scientific Officer of PharmaSeq, Inc. Dr. Mandecki received a B.S. in Physics from the University of Warsaw, Poland, and a Ph.D. in Biochemistry from the Polish Academy of Sciences. He was an R&D Manager at Abbott Laboratories for several years and Director of Molecular Biology at DGI Biotechnologies. In addition to his accomplishments in the area of RFID, he has made important contributions in the area of molecular biology, in vitro diagnostics and drug discovery. Dr. Mandecki has over 20 patents and patent applications pending. He is an author of over sixty publications in peer reviewed scientific journals and an Adjunct Professor at the University of Medicine and Dentistry of New Jersey.

Company Profile (PharmaSeq)

PharmaSeq logo
PharmaSeq, Inc. specializes in innovative RFID solutions based on technology of light-activated microtransponders. This privately held company was founded in 1999 and is located near Princeton, NJ. Its major products are the microtransponder chips and custom ID readers. Current applications include tagging of small animals, such as laboratory mice, as well as tracking and authentication. In addition, PharmaSeq is developing instrumentation for protein and DNA-based diagnostics. The Company has nine U.S. and international patents covering microtransponder-based assays and technology.
View PharmaSeq Timeline